Abstract
BACKGROUND: With the success in developing drugs able to slow cognitive decline in Alzheimer’s disease (AD), the disease managements of AD become aggressive and positive. The target patients of drug are the prodromal AD, i.e. clinical dementia rating being 0.5 and mini‐mental status examination being between 20 and 28, having positive amyloid pathology. In practical, it seems to have big burdens in finding prodromal AD patients have positive amyloid pathology at neurological departments in hospitals. The impact of drug in managing AD is intensively suppressed. A pre‐screening tool for finding target patients is needed. By integrating the reported assessments of prodromal AD and positive amyloid positron emission tomography (PET) using plasma biomarkers, a pre‐screening flow chart is proposed. METHOD: A multi‐centered study was done to validate assessments of amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease dementia (ADD) using plasm concentration ratio of amyloid β 1‐42 (Aβ(1‐42)) to Aβ(1‐40) (Aβ(1‐42)/Aβ(1‐40)) and the concentration product of Aβ(1‐42) and total tau protein (T‐Tau) (Aβ(1‐42)xT‐Tau), which were assayed with immunomagnetic reduction (IMR). Explorations of pre‐screening model of amyloid pathology in prodromal using plasma Aβ(1‐42) and APOE genotype in prodromal AD was investigated in the multi‐centered study. RESULT: The levels of Aβ(1‐42)/Aβ(1‐40) or Aβ(1‐42)xT‐Tau in plasma show high accuracy (> 85%) in assessing prodromal AD. The combination of plasma Aβ(1‐42) and APOE genotypes show the high prediction (> 84%) in positive amyloid PET in prodromal AD. These results demonstrate the feasibilities of assessing prodromal AD using plasma Aβ(1‐42)/Aβ(1‐40) or Aβ(1‐42)xT‐Tau, followed by combing plasma Aβ(1‐42) with APOE genotypes to predict the positive amyloid PET. CONCLUSION: Such pre‐screening flow chart could breakdown the bottleneck of finding prodromal AD having positive amyloid PET in clinic and promote the impact of drug to the managements of AD.